| Epigenetic changes in the myelodysplastic syndrome. | |
| | |
MedLine Citation:
|
PMID: 20359628 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Epigenetic mechanisms, such as DNA methylation and histone modifications, drive stable, clonally propagated changes in gene expression and can therefore serve as molecular mediators of pathway dysfunction in neoplasia. Myelodysplastic syndrome (MDS) is characterized by frequent epigenetic abnormalities, including the hypermethylation of genes that control proliferation, adhesion, and other characteristic features of this leukemia. Aberrant DNA hypermethylation is associated with a poor prognosis in MDS that can be accounted for by more rapid progression to acute myeloid leukemia. In turn, treatment with drugs that modify epigenetic pathways (DNA methylation and histone deacetylation inhibitors) induces durable remissions and prolongs life in MDS, offering some hope and direction in the future management of this deadly disease. |
| | |
Authors:
|
Jean-Pierre Issa |
Related Documents
:
|
20360128 - Single-tube analysis of dna methylation with silica superparamagnetic beads. 18788878 - Dna methylation changes during cleft palate formation induced by retinoic acid in mice. 18006818 - Examination of igf2 and h19 loss of imprinting in bladder cancer. 18222408 - Analysis of dna methylation in different maize tissues. 6220808 - Studies on the properties of p1 site-specific recombination: evidence for topologically... 104728 - Transformation in bacillus subtilis with nitrogen mustard crosslinked dna. effect on co... |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: Hematology/oncology clinics of North America Volume: 24 ISSN: 1558-1977 ISO Abbreviation: Hematol. Oncol. Clin. North Am. Publication Date: 2010 Apr |
Date Detail:
|
Created Date: 2010-04-02 Completed Date: 2010-06-17 Revised Date: 2011-08-01 |
Medline Journal Info:
|
Nlm Unique ID: 8709473 Medline TA: Hematol Oncol Clin North Am Country: United States |
Other Details:
|
Languages: eng Pagination: 317-30 Citation Subset: IM |
Copyright Information:
|
Copyright (c) 2010 Elsevier Inc. All rights reserved. |
Affiliation:
|
Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe, Houston, TX 77030, USA. jpissa@mdanderson.org |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acetylation
/
drug effects Acute Disease Azacitidine / analogs & derivatives, therapeutic use Cell Transformation, Neoplastic / drug effects DNA Methylation / drug effects Epigenesis, Genetic* / drug effects Histone Deacetylase Inhibitors / therapeutic use Histone Deacetylases / physiology Histones / metabolism Humans Leukemia, Myeloid / etiology, prevention & control Methylation Myelodysplastic Syndromes / drug therapy, genetics* Neoplasms / genetics, metabolism Protein Processing, Post-Translational / drug effects |
| Grant Support | |
ID/Acronym/Agency:
|
CA098006/CA/NCI NIH HHS; CA100632/CA/NCI NIH HHS; CA121104/CA/NCI NIH HHS; P01 CA108631-050003/CA/NCI NIH HHS; P50 CA100632-010001/CA/NCI NIH HHS; P50 CA100632-060001/CA/NCI NIH HHS; P50 CA100632-06S1/CA/NCI NIH HHS; R01 CA121104-03/CA/NCI NIH HHS; R01 CA121104-05/CA/NCI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Histone Deacetylase Inhibitors; 0/Histones; 2353-33-5/decitabine; 320-67-2/Azacitidine; EC 3.5.1.98/Histone Deacetylases |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The Genetic Basis of Myelodysplastic Syndromes.
Next Document: Immunosuppression for myelodysplastic syndrome: how bench to bedside to bench research led to succes...